Cargando…

The RAAS Goodfellas in Cardiovascular System

In the last two decades, the study of the renin–angiotensin–aldosterone system (RAAS) has revealed a counterregulatory protective axis. This protective arm is characterized by ACE2/Ang 1-7/MasR and Ang 1-9 that largely counteracts the classic arm of the RAAS mediated by ACE/Ang II/AT1R/aldosterone a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caputo, Ilaria, Bertoldi, Giovanni, Driussi, Giulia, Cacciapuoti, Martina, Calò, Lorenzo A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649249/ https://www.ncbi.nlm.nih.gov/pubmed/37959338 http://dx.doi.org/10.3390/jcm12216873

Ejemplares similares

Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?
por: Bertoldi, Giovanni, et al.
Publicado: (2023)

Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
por: Bernardi, Stella, et al.
Publicado: (2016)

The Pivotal Role of Oxidative Stress in the Pathophysiology of Cardiovascular-Renal Remodeling in Kidney Disease
por: Ravarotto, Verdiana, et al.
Publicado: (2021)

Pathomechanism of oxidative stress in cardiovascular-renal remodeling and therapeutic strategies
por: Ravarotto, Verdiana, et al.
Publicado: (2022)

Oxidative Stress and Cardiovascular-Renal Damage in Fabry Disease: Is There Room for a Pathophysiological Involvement?
por: Ravarotto, Verdiana, et al.
Publicado: (2018)

RAAS inhibition and mortality in hypertension
por: Ferrari, Roberto
Publicado: (2013)

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
por: Ghazi, Lama, et al.
Publicado: (2017)

Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008)

NATRIURETIC PEPTIDE SYSTEM AND CARDIOVASCULAR DISEASE
por: Federico, Cacciapuoti
Publicado: (2010)

The RAAS Axis and SARS-CoV-2: From Oral to Systemic Manifestations
por: Maranduca, Minela Aida, et al.
Publicado: (2022)

RAAS, ACE2 and COVID-19; a mechanistic review
por: Elshafei, Ahmed, et al.
Publicado: (2021)

RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19
por: Dutsch, Alexander, et al.
Publicado: (2023)

Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
por: Wang, James Jiqi, et al.
Publicado: (2020)

The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
por: Hassani, Bahareh, et al.
Publicado: (2023)

COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

RAAS: A Convergent Player in Ischemic Heart Failure and Cancer
por: Garcia-Garduño, Texali C., et al.
Publicado: (2021)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
por: Gnudi, Luigi, et al.
Publicado: (2010)

Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin–angiotensin-aldosterone system (RAAS) dysregulation
por: Augustine, Robin, et al.
Publicado: (2022)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

The Role of Systolic Blood Pressure Reduction in Diastolic Dysfunction: RAAS Inhibition versus Non-RAAS Blood Pressure Lowering
por: Park, Sung-Ji
Publicado: (2020)

Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter’s and Gitelman’s syndrome patients
por: Calò, Lorenzo A., et al.
Publicado: (2020)

Gitelman's and Bartter's Syndromes: From Genetics to the Molecular Basis of Hypertension and More
por: Ravarotto, Verdiana, et al.
Publicado: (2022)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

Heavy Ion RAA summary Plots 2022
por: The ATLAS collaboration
Publicado: (2022)

Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling
por: Wehbe, Zena, et al.
Publicado: (2020)

Development and Application of RAA Nucleic Acid Test Strip Assay and Double RAA Gel Electrophoresis Detection Methods for ASFV and CSFV
por: Wu, Keke, et al.
Publicado: (2022)

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
por: Zhang, Jishou, et al.
Publicado: (2020)

Aging- and gender-related modulation of RAAS: potential implications in COVID-19 disease
por: Monteonofrio, Laura, et al.
Publicado: (2020)

Novel RAAS agonists and antagonists: clinical applications and controversies
por: Romero, Cesar A., et al.
Publicado: (2015)

The Relationship between Renin–Angiotensin–Aldosterone System (RAAS) Activity, Osteoporosis and Estrogen Deficiency in Type 2 Diabetes
por: Mkhize, Bongeka Cassandra, et al.
Publicado: (2023)

Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination
por: Cagnoni, Francesca, et al.
Publicado: (2010)

Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations
por: Leoncini, Giovanna, et al.
Publicado: (2020)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
por: Burrello, Jacopo, et al.
Publicado: (2020)

RAA-Cas12a-Tg: A Nucleic Acid Detection System for Toxoplasma gondii Based on CRISPR-Cas12a Combined with Recombinase-Aided Amplification (RAA)
por: Ma, Qiao-Ni, et al.
Publicado: (2021)

Heavy Ion Jet RAA Summary Plots 2023
por: The ATLAS collaboration
Publicado: (2023)

RAAS inhibitors do not increase the risk of COVID-19
por: Fernández-Ruiz, Irene
Publicado: (2020)

Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction
por: Farhadi, Susan A. S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4g2pkd9tb74nkq3b30hn6sfk64